Table 3

Subgroup analysis of all-cause mortality according to disease course

ItemEarly antiviral subgroupLate antiviral subgroup
P valueAdjusted OR (95% CI)P valueAdjusted OR (95% CI)
Paxlovid vs azvudine0.6191.179 (0.613 to 2.265)0.6471.076 (0.785 to 1.476)
Age0.0101.034 (1.008 to 1.063)<0.0011.027 (1.014 to 1.040)
Course0.4020.873 (0.633 to 1.200)0.4731.014 (0.976 to 1.052)
One dose of vaccination0.9900.000 (−)0.3523.155 (0.187 to 32.985)
Two doses of vaccination0.4000.182 (0.000 to 7.194)0.5861.589 (0.215 to 7.117)
Three doses of vaccination0.9390.927 (0.155 to 8.668)0.4781.258 (0.685 to 2.451)
Immunocompromised status0.0060.308 (0.128 to 0.686)0.7821.056 (0.717 to 1.544)
Steroids0.3071.515 (0.695 to 3.452)<0.0012.914 (1.718 to 5.275)
Tocilizumab<0.0017.201 (2.512 to 22.161)0.0112.038 (1.649 to 3.473)
Baricitinib0.5761.532 (0.298 to 6.300)0.7121.131 (0.575 to 2.137)
Immunoglobulins0.0023.827 (1.656 to 8.887)<0.0012.396 (0.717 to 1.544)
Bacteria0.2110.543 (0.195 to 1.344)<0.0012.244 (1.523 to 3.291)
Candida0.4020.726 (0.350 to 1.462)<0.0012.323 (1.656 to 3.265)
SOFA score on Day 1<0.0011.855 (1.514 to 2.312)<0.0011.397 (1.284 to 1.522)
  • SOFA, Sequential Organ Failure Assessment;